Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innocan Pharma Corp (CSE: INNO )

0.2700 UNCHANGED
Streaming Delayed Price Updated: 9:30 AM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.2700
Bid (Size) 0.2900 (30,000)
Ask (Size) 0.2900 (46,000)
Prev. Close 0.2700
Today's Range 0.2700 - 0.2700
52wk Range 0.1800 - 0.5200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
Innocan Pharma's 2023 earnings report: Revenue soars 534%, operating loss down 61%, $1.5M capital raise. CEO shares strategic vision. 
Via Benzinga
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are... 
Via Benzinga
Exposures Product Safety

Performance

YTD
-12.90%
-12.90%
1 Month
-5.26%
-5.26%
3 Month
-8.47%
-8.47%
6 Month
-12.90%
-12.90%
1 Year
+28.57%
+28.57%

More News

Read More
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
Via Benzinga
Topics Cannabis
Exposures Cannabis
More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare
Via Benzinga
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
Via Benzinga
Industry Update: Innocan Pharma Accelerates Commercialization in Europe Following Impressive Revenue Growth
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Innovative Delivery Systems Create Unique Opportunities in the Billion-Dollar Pain Market (CSE: INNO)
Via AB Newswire
Topics Cannabis
Exposures Cannabis
Innocan Pharma Provides an Operational Update
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
Via Newsfile
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Via Newsfile
Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Engages Ayurcann Inc. to Manufacture and Distribute Innocan's CBD Topicals in Canada
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Former Israeli Minister of Science and Technology and Highly Influential Venture Capitalist to Join Innocan Pharma's Advisory Committee
Via Newsfile
Topics Artificial Intelligence Supply Chain
Exposures Artificial Intelligence COVID-19 Supply Chain
Innocan Pharma Announces Filing of International Patent Application for Topical Treatment for Diabetic Symptoms
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma and Health Investment Group S.A. Sign Exclusive Distribution Agreement for Poland
Via Newsfile
Topics Economy Supply Chain
Exposures COVID-19 Economy Supply Chain
Innocan Pharma's CBD Integrated Anti-Aging Sleeping Mask Demonstrates a Reduction of the Appearance of Wrinkles by up to 28.8% in 4 Weeks of Clinical Study
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Clinical Study Validates Innocan Pharma's SHIR(R) CBD Eye Serum as an Anti-Puffiness Solution
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Among Leading CBD Pharma Companies to Participate at Lytham Partners Summer 2021 Investor Conference
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.